Cozadd Bruce C's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Aug 3, 2022
- Accession no.
- 0001765581-22-000073
- Filed
- Aug 3, 2022
- Trade date
- Aug 1, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.13M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cozadd Bruce CCIK 0001193210 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2022 | Ordinary Shares | MOption exerciseAcquired | +9,632 | $46.83 | +$451,066.56 | 361,544 | Direct | |
| Aug 1, 2022 | Ordinary Shares | MOption exerciseAcquired | +68 | $59.13 | +$4,020.84 | 361,612 | Direct | |
| Aug 1, 2022 | Ordinary Shares | SSaleDisposed | −2,600 | $153.48F2 | −$399,048 | 359,012 | Direct | |
| Aug 1, 2022 | Ordinary Shares | SSaleDisposed | −2,601 | $154.50F3 | −$401,854.5 | 356,411 | Direct | |
| Aug 1, 2022 | Ordinary Shares | SSaleDisposed | −1,100 | $155.27F4 | −$170,797 | 355,311 | Direct | |
| Aug 1, 2022 | Ordinary Shares | SSaleDisposed | −1,000 | $154.94 | −$154,940 | 354,311 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2022 | Ordinary Shares | MOption exerciseDisposed | −9,632 | $0.00 | $0 | 0 | Direct | |
| Aug 1, 2022 | Ordinary Shares | MOption exerciseDisposed | −68 | $0.00 | $0 | 72,605 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.01 to $153.935. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F3
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $154.01 to $154.95. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F4
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $155.015 to $155.66. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.